Brokerages Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) Price Target at $9.56

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned an average rating of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $9.56.

Several equities research analysts recently commented on the stock. HC Wainwright raised shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price objective on the stock in a research report on Thursday, December 26th. Wells Fargo & Company reduced their price objective on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $8.00 to $2.00 in a research report on Monday, November 11th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 price objective (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Readystate Asset Management LP bought a new stake in shares of RAPT Therapeutics in the 3rd quarter valued at about $36,000. Bank of New York Mellon Corp raised its stake in RAPT Therapeutics by 24.0% in the second quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock valued at $349,000 after buying an additional 22,175 shares during the period. JPMorgan Chase & Co. lifted its position in shares of RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after buying an additional 25,130 shares during the last quarter. Barclays PLC boosted its stake in shares of RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares during the period. Finally, Los Angeles Capital Management LLC increased its holdings in shares of RAPT Therapeutics by 66.2% during the 2nd quarter. Los Angeles Capital Management LLC now owns 84,586 shares of the company’s stock worth $258,000 after acquiring an additional 33,692 shares during the last quarter. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Price Performance

Shares of RAPT Therapeutics stock opened at $1.45 on Friday. The company has a market capitalization of $50.69 million, a P/E ratio of -0.52 and a beta of 0.07. The business has a 50-day moving average of $1.46 and a two-hundred day moving average of $2.07. RAPT Therapeutics has a 1 year low of $0.79 and a 1 year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, equities analysts anticipate that RAPT Therapeutics will post -2.86 EPS for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.